Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adebrelimab Combined With Apatinib and Tegafur in Esophageal Squamous Cell Carcinoma
NCT06339619Phase 2Recruiting
- Sponsor
- Sun Yat-sen Memorial Hospital
- Start
- Mar 2024
- Primary completion
- Mar 2028
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of adebrelimab in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by Sun Yat-sen Memorial Hospital. Started Mar 2024; status: recruiting.
02
Drugs
adebrelimab
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT06339619.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06339619.